RT Journal Article
T1 Epigenetic changes in the metabolically healthy obese: A case-control versus a prospective study
A1 Linares-Pineda, Teresa María
A1 Boughanem Lakhal, Hatim
A1 Gutiérrez Repiso, Carolina
A1 Macías-González, Manuel
A1 Andrés-León, Eduardo
A1 Rojo-Martínez, Gemma
A1 Valdés, Sergio
K1 Obesidad
AB Obesity has become a worldwide health problem, in which latest statistics reported an increased trend over the last years. Accordingly, long-term obesity is involved in an increased risk of developing several metabolic diseases, such as cardiovascular diseases, insulin resistance or type 2 diabetes. Although it is common to find obesity-related disorders in the majority of individuals with obesity, some of them do not show metabolic complications.1 Obese people without these metabolic disorders are defined as metabolically healthy obesity (MHO) individuals, whereas those who present metabolic complications are known as metabolically unhealthy obesity (MUO) subjects.2 Importantly, the prevalence of this healthy phenotype varies widely, in which a correct diagnosis is critical for a good prognosis.2, 3 Nevertheless, the variability of this prevalence may be due to the nature of related-study designs and the studied populations or the confounding variables considered. Therefore, conducting appropriately designed studies to evaluate important clinical research questions is crucial, to elucidate the impact of MHO in the progression of detrimental obesity-related phenotypes.4 In this case, epigenetic arises as a valuable tool for clinical applications. Epigenetic mechanisms might be implicated in the regulation of several metabolic disorders.5 However, until now, only a few studies have been conducted to understand the epigenetic changes in individuals with MHO and MUO.6-8Therefore, we hypothesized that epigenetic changes may be involved in the development and the transition from MHO to MUO phenotype. Consequently, the aim of this study was to analyze the epigenome-wide DNA methylation study in peripheral blood mononuclear cells (PMBCs) from participants with MHO and MUO, by using two study designs, such as case-control and prospective approaches.
PB Wiley
YR 2022
FD 2022-03-28
LK https://hdl.handle.net/10630/24638
UL https://hdl.handle.net/10630/24638
LA spa
NO Linares-Pineda, TM, Boughanem, H, Gutiérrez-Repiso, C, et al. Epigenetic changes in the metabolically healthy obese: A case-control versus a prospective study. Eur J Clin Invest. 2022; 52:e13783. doi:10.1111/eci.13783
NO TMLP and CGR were supported by a grant from Instituto de Salud Carlos III (FI19/00178 and CP20/00066, respectively). HB is supported by a predoctoral fellowship ("Plan Propio IBIMA 2020 A.1 Contratos predoctorales", Ref.: predoc20_002). SM, MMG and GRM are supported by Nicolas Monardes program from the Consejería de Salud de la Junta de Andalucía (RC-0008-2021, RC-0001-2018 and C-0060-2012, respectively). EAL was recipient of a postdoctoral fellowship from regional Andalusian Government (Ref: 2020_DOC_00541). This work was supported in part by a grant from the Instituto de Salud Carlos III (PI15-01350). This study has been co-funded by FEDER funds (“A way to make Europe”). CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) and CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) are ISCIII. Funding for open access charge: Universidad de Málaga / CBUA
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 21 ene 2026